Chronic Immune-Related Adverse Effects Common in Patients With Resected Melanoma Treated With Anti-PD-1 Therapy

Source: Pharmacy Times, August 2023

Researchers found an increase in patients with melanoma who experience chronic immune-related adverse effects at 18 months compared to a previous study with a follow-up point of 6 months.

In patients with high-risk resected melanoma treated with anti-programmed cell death-1 (anti-PD-1) therapy, chronic immune-related adverse effects (irAEs) were highly prevalent and often persisted long-term, according to the results of a study published in the Journal of the American Medical Association.

Immune checkpoint inhibitors that target PD-1 have become a preferred first-line treatment for melanoma and can prolong recurrence-free survival (RFS) when used as adjuvant therapy. At the same time, it can cause autoimmune AEs that can involve multiple organs throughout the body and may persist for up to 12 weeks.